NuCana is expected to report a Q3 2026 net loss with a consensus EPS estimate of -$0.75 on zero revenue, as the stock trades near $0.94 with an average analyst price target of $2.50.

Investors are primarily focused on clinical updates for NUC-7738, specifically the final Phase 2 expansion data in metastatic melanoma patients expected by the end of 2026.

The company has successfully extended its cash runway into 2029 by significantly narrowing operating losses and prioritizing its lead ProTide candidates following earlier pipeline adjustments. This report will be critical for assessing the regulatory path forward for NUC-7738 and the potential impact of its newly granted European composition-of-matter patents.